RU2011103170A - Твердые дозированные составы телкагепанта калия - Google Patents
Твердые дозированные составы телкагепанта калия Download PDFInfo
- Publication number
- RU2011103170A RU2011103170A RU2011103170/15A RU2011103170A RU2011103170A RU 2011103170 A RU2011103170 A RU 2011103170A RU 2011103170/15 A RU2011103170/15 A RU 2011103170/15A RU 2011103170 A RU2011103170 A RU 2011103170A RU 2011103170 A RU2011103170 A RU 2011103170A
- Authority
- RU
- Russia
- Prior art keywords
- oxo
- pharmaceutical preparation
- solid dosage
- difluorophenyl
- imidazo
- Prior art date
Links
- 239000007787 solid Substances 0.000 title claims abstract 34
- 239000000203 mixture Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract 32
- -1 2,3-difluorophenyl Chemical group 0.000 claims abstract 26
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims abstract 18
- 229910052700 potassium Inorganic materials 0.000 claims abstract 10
- 239000011591 potassium Substances 0.000 claims abstract 10
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims abstract 9
- 239000008180 pharmaceutical surfactant Substances 0.000 claims abstract 8
- 239000004475 Arginine Substances 0.000 claims abstract 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000002360 preparation method Methods 0.000 claims abstract 4
- 229920001400 block copolymer Polymers 0.000 claims abstract 2
- 239000002736 nonionic surfactant Substances 0.000 claims abstract 2
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract 2
- 239000008280 blood Substances 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 238000001237 Raman spectrum Methods 0.000 claims 3
- CGDZXLJGHVKVIE-DNVCBOLYSA-N n-[(3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide Chemical compound FC1=CC=CC([C@H]2CN(CC(F)(F)F)C(=O)[C@H](NC(=O)N3CCC(CC3)N3C(NC4=NC=CC=C43)=O)CC2)=C1F CGDZXLJGHVKVIE-DNVCBOLYSA-N 0.000 claims 3
- 238000000279 solid-state nuclear magnetic resonance spectrum Methods 0.000 claims 3
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 claims 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13354208P | 2008-06-30 | 2008-06-30 | |
| US61/133,542 | 2008-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011103170A true RU2011103170A (ru) | 2012-08-10 |
Family
ID=41057505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011103170/15A RU2011103170A (ru) | 2008-06-30 | 2009-06-29 | Твердые дозированные составы телкагепанта калия |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20100009967A1 (enExample) |
| EP (1) | EP2303238A1 (enExample) |
| JP (2) | JP2011526909A (enExample) |
| KR (1) | KR20110025926A (enExample) |
| CN (1) | CN102076330A (enExample) |
| AR (1) | AR072395A1 (enExample) |
| AU (1) | AU2009267145A1 (enExample) |
| CA (1) | CA2728547A1 (enExample) |
| CR (1) | CR20110038A (enExample) |
| DO (1) | DOP2010000409A (enExample) |
| IL (1) | IL209833A0 (enExample) |
| MX (1) | MX2010014524A (enExample) |
| RU (1) | RU2011103170A (enExample) |
| SV (1) | SV2010003774A (enExample) |
| TW (1) | TW201004954A (enExample) |
| WO (1) | WO2010002763A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5243548B2 (ja) * | 2007-10-25 | 2013-07-24 | プロテウス デジタル ヘルス， インコーポレイテッド | 情報システムのための流体伝達ポート |
| EP2249833B1 (en) * | 2008-02-05 | 2012-10-17 | Merck Sharp & Dohme Corp. | Prodrugs of cgrp receptor antagonist |
| WO2017001434A1 (en) * | 2015-06-29 | 2017-01-05 | Galderma Research & Development | Cgrp receptor antagonist compounds for topical treatment of skin disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| ATE209491T1 (de) * | 1997-03-13 | 2001-12-15 | Hexal Ag | Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen |
| US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| JO2355B1 (en) * | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| AU2007238896A1 (en) * | 2006-04-10 | 2007-10-25 | Merck Sharp & Dohme Corp. | CGRP antagonist salt |
| CA2662748A1 (en) * | 2006-09-08 | 2008-03-13 | Merck & Co., Inc. | Liquid pharmaceutical formulations for oral administration of a cgrp antagonist |
-
2009
- 2009-06-29 JP JP2011516753A patent/JP2011526909A/ja not_active Withdrawn
- 2009-06-29 AU AU2009267145A patent/AU2009267145A1/en not_active Abandoned
- 2009-06-29 RU RU2011103170/15A patent/RU2011103170A/ru not_active Application Discontinuation
- 2009-06-29 US US12/493,311 patent/US20100009967A1/en not_active Abandoned
- 2009-06-29 CN CN2009801252261A patent/CN102076330A/zh active Pending
- 2009-06-29 AR ARP090102404A patent/AR072395A1/es unknown
- 2009-06-29 WO PCT/US2009/049009 patent/WO2010002763A1/en not_active Ceased
- 2009-06-29 CA CA2728547A patent/CA2728547A1/en not_active Abandoned
- 2009-06-29 MX MX2010014524A patent/MX2010014524A/es not_active Application Discontinuation
- 2009-06-29 TW TW098121909A patent/TW201004954A/zh unknown
- 2009-06-29 EP EP09774214A patent/EP2303238A1/en not_active Withdrawn
- 2009-06-29 KR KR1020107029334A patent/KR20110025926A/ko not_active Withdrawn
-
2010
- 2010-12-07 IL IL209833A patent/IL209833A0/en unknown
- 2010-12-21 SV SV2010003774A patent/SV2010003774A/es not_active Application Discontinuation
- 2010-12-30 DO DO2010000409A patent/DOP2010000409A/es unknown
-
2011
- 2011-01-21 CR CR20110038A patent/CR20110038A/es not_active Application Discontinuation
- 2011-07-13 JP JP2011155043A patent/JP2011246478A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010014524A (es) | 2011-02-24 |
| CA2728547A1 (en) | 2010-01-07 |
| CN102076330A (zh) | 2011-05-25 |
| AU2009267145A1 (en) | 2010-01-07 |
| TW201004954A (en) | 2010-02-01 |
| EP2303238A1 (en) | 2011-04-06 |
| CR20110038A (es) | 2011-03-16 |
| WO2010002763A1 (en) | 2010-01-07 |
| AR072395A1 (es) | 2010-08-25 |
| JP2011526909A (ja) | 2011-10-20 |
| JP2011246478A (ja) | 2011-12-08 |
| KR20110025926A (ko) | 2011-03-14 |
| IL209833A0 (en) | 2011-02-28 |
| US20100009967A1 (en) | 2010-01-14 |
| SV2010003774A (es) | 2011-03-23 |
| DOP2010000409A (es) | 2011-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2822942B1 (en) | Benzodioxanes for inhibiting leukotriene production | |
| WO2011160136A3 (en) | Progesterone containing oral dosage forms and related methods | |
| PE20130378A1 (es) | Formulaciones de apixaban | |
| AU2007276804A1 (en) | Inhibitors of undecaprenyl pyrophosphate synthase | |
| UA109774C2 (uk) | Кристалічні форми саксагліптину та процес його одержання (варіанти) | |
| WO2010018109A3 (en) | Substituted aminotetralines | |
| CA2935089C (en) | 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof | |
| EA201400679A1 (ru) | Композиция сухого порошка производного азола для ингаляции | |
| RU2008145714A (ru) | Пуриновые производные в качестве активатора аденозинового рецептора | |
| TW200815410A (en) | Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof | |
| RU2011103170A (ru) | Твердые дозированные составы телкагепанта калия | |
| US9446091B2 (en) | Caspofungin or salts thereof with high purity, as well as preparation method and use thereof | |
| NO20082181L (no) | Formuleringer av Fispemifen | |
| EA201070780A1 (ru) | Активный фармацевтический ингредиент на твердом аморфном носителе и с повышенной растворимостью | |
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| JP2011526909A5 (enExample) | ||
| BR112020009507A2 (pt) | pirazolopirimidinas tendo atividade contra o vírus sincicial respiratório (rsv) | |
| EP3746444A1 (en) | Cycloalkyl substituted pyrazolopyrimidines having activity against rsv | |
| ES2206326T3 (es) | Piranoindoles para tratar el glaucoma. | |
| MX2013011937A (es) | Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina. | |
| WO2025049821A1 (en) | Stat6 degraders and uses thereof | |
| WO2024064080A1 (en) | Stat6 degraders and uses thereof | |
| PE20081701A1 (es) | Derivados de pirrolopiridina-2-carboxamidas y su preparacion | |
| JP2014214156A (ja) | モルフィナン誘導体の結晶、その製造方法、およびそれを用いた医薬組成物 | |
| EP3022194B1 (en) | Inhibitors of leukotriene production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20120702 |